Alkem Laboratories Peer Comparison
NSE: ALKEM | BSE: 539523
₹5,355.00
As on 28-Aug-2026IST
Market cap
₹63,969 Cr
Revenue (TTM)
₹15,081 Cr
P/E Ratio
29.6
P/B Ratio
4.5
Div. Yield
1 %
| Alkem Laboratories | Zydus Lifesciences | Lupin | Mankind Pharma | Dr. Reddy'S Labs | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
63,969 | 1,18,404 | 99,455 | 98,599 | 98,309 |
Revenue (₹ Cr) |
15,081 | 28,592 | 29,967 | 14,738 | 33,228 |
Net Profit (₹ Cr) |
2,206.30 | 4,492.20 | 5,551.01 | 2,055.11 | 3,169.30 |
Net Margin (%) |
14.07 | 14.92 | 18.23 | 13.64 | 9.15 |
RoE (%) |
16.76 | 18.78 | 28.32 | 13.60 | 8.72 |
Price to Earnings |
29.65 | 26.24 | 17.99 | 48.27 | 30.51 |
Price-To-Book |
4.47 | 4.39 | 4.18 | 5.86 | 2.58 |
Income Statement (₹ Cr)
| Alkem Laboratories | Zydus Lifesciences | Lupin | Mankind Pharma | Dr. Reddy'S Labs | |
|---|---|---|---|---|---|
|
Operating Revenue
|
15,081.28 | 28,591.70 | 29,966.58 | 14,737.88 | 33,227.90 |
|
Total Income
|
15,680.89 | 30,111.40 | 30,442.31 | 15,061.79 | 34,650.70 |
|
Total Expenditure
|
12,049.07 | 21,334.70 | 20,428.27 | 10,911.05 | 28,088.10 |
|
EBITDA
|
3,032.21 | 7,257.00 | 9,538.31 | 3,826.83 | 5,139.80 |
|
Depreciation
|
394.57 | 1,724.60 | 1,529.37 | 893.20 | 2,119.30 |
|
EBIT
|
2,637.64 | 5,532.40 | 8,008.94 | 2,933.63 | 3,020.50 |
|
Interest
|
177.62 | 510.20 | 452.37 | 578.61 | 416.30 |
|
Other Income
|
599.61 | 1,519.70 | 475.73 | 323.91 | 1,422.80 |
|
Exceptional Items
|
-187.76 | -534.80 | -557.91 | -129.75 | 0.00 |
|
Profit before Tax
|
2,871.87 | 6,007.10 | 7,474.39 | 2,549.18 | 4,027.00 |
|
Provision for Tax
|
665.57 | 1,514.90 | 1,923.38 | 494.07 | 857.70 |
|
Profit after Tax
|
2,206.30 | 4,492.20 | 5,551.01 | 2,055.11 | 3,169.30 |
Liabilities (₹ Cr)
| Alkem Laboratories | Zydus Lifesciences | Lupin | Mankind Pharma | Dr. Reddy'S Labs | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
13,820.10 | 27,111.40 | 22,448.27 | 16,300.34 | 37,891.50 |
|
Minority Interest
|
-46.73 | -79.70 | -22.18 | -24.90 | 38.90 |
|
Non-Current Liabilities
|
1,741.34 | 7,112.50 | 3,200.22 | 5,011.23 | 3,145.10 |
|
Current Liabilities
|
4,782.70 | 15,711.90 | 12,651.24 | 6,507.25 | 16,747.40 |
|
Total Liabilities
|
20,857.85 | 50,672.60 | 38,146.06 | 27,754.83 | 56,576.70 |
Assets (₹ Cr)
| Alkem Laboratories | Zydus Lifesciences | Lupin | Mankind Pharma | Dr. Reddy'S Labs | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
6,708.01 | 31,677.20 | 11,888.82 | 20,274.65 | 27,204.00 |
|
Current Assets
|
12,210.52 | 19,906.10 | 24,027.38 | 6,954.20 | 30,179.30 |
|
Total Assets
|
20,857.85 | 50,672.60 | 38,146.06 | 27,754.83 | 56,576.70 |
|
Total Debt*
|
1,623.50 | 11,769.50 | 5,910.20 | 6,021.78 | 7,734.10 |
|
Net Current Assets
|
7,427.82 | 4,194.20 | 11,376.14 | 446.95 | 13,431.90 |
|
Contingent Liabilities
|
1,113.14 | 989.90 | 1,094.02 | 924.77 | 336.14 |
Cashflow (₹ Cr)
| Alkem Laboratories | Zydus Lifesciences | Lupin | Mankind Pharma | Dr. Reddy'S Labs | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
1,963.03 | 2,116.60 | 7,334.50 | 3,121.29 | 5,673.70 |
|
Cash Flow from Investing Activities
|
-1,667.21 | -8,296.10 | -3,864.59 | -196.42 | -6,549.30 |
|
Cash from Financing Activities
|
-503.40 | 5,806.90 | -845.87 | -2,952.69 | 829.00 |
|
Net Cash Inflow / Outflow
|
-207.58 | -372.60 | 2,624.04 | -27.82 | -46.60 |
Ratios
Profitability Ratios
| Alkem Laboratories | Zydus Lifesciences | Lupin | Mankind Pharma | Dr. Reddy'S Labs | |
|---|---|---|---|---|---|
|
ROCE (%)
|
21.28 | 21.39 | 28.86 | 13.24 | 13.75 |
|
ROE (%)
|
16.76 | 18.78 | 28.32 | 13.60 | 8.72 |
|
ROA (%)
|
11.44 | 10.03 | 16.43 | 7.36 | 5.89 |
|
EBIT Margin (%)
|
17.49 | 19.35 | 26.73 | 19.91 | 9.09 |
|
Net Margin (%)
|
14.07 | 14.92 | 18.23 | 13.64 | 9.15 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Alkem Laboratories | Zydus Lifesciences | Lupin | Mankind Pharma | Dr. Reddy'S Labs | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
13.36 | 21.11 | 28.19 | 14.16 | -0.87 |
|
EBIT Growth (%)
|
15.78 | -8.99 | 77.03 | 19.45 | -55.06 |
|
Net Profit Growth (%)
|
-5.47 | -3.14 | 49.13 | 8.09 | -44.66 |
|
EPS Growth (%)
|
0.11 | 4.31 | 60.86 | 12.27 | -43.29 |
|
Book Value Growth (%)
|
15.36 | 13.19 | 30.75 | 13.74 | 12.99 |
Valuation Ratios
| Alkem Laboratories | Zydus Lifesciences | Lupin | Mankind Pharma | Dr. Reddy'S Labs | |
|---|---|---|---|---|---|
|
Price / Earnings
|
28.11 | 24.23 | 16.68 | 45.88 | 30.51 |
|
Price / Book Value
|
4.47 | 4.39 | 4.18 | 5.86 | 2.58 |
|
Dividend Yield (%)
|
0.99 | 0.08 | 0.83 | 0.04 | 0.68 |
|
EV/EBITDA
|
20.82 | 16.95 | 10.08 | 26.81 | 19.27 |
|
Market Cap (₹ Cr)
|
63,401.06 | 87,643.18 | 1,05,737.27 | 82,801.75 | 1,04,763.81 |
Solvency Ratios
| Alkem Laboratories | Zydus Lifesciences | Lupin | Mankind Pharma | Dr. Reddy'S Labs | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.04 | 0.12 | 0.07 | 0.17 | 0.00 |
|
Short term debt to equity ratio
|
0.08 | 0.16 | 0.18 | 0.04 | 0.16 |
|
Current Ratio
|
2.55 | 1.27 | 1.90 | 1.07 | 1.80 |
|
Quick Ratio
|
1.86 | 0.91 | 1.42 | 0.74 | 1.35 |
|
Interest Coverage
|
17.17 | 12.77 | 17.52 | 5.41 | 10.67 |
Operating Efficiency Ratios
| Alkem Laboratories | Zydus Lifesciences | Lupin | Mankind Pharma | Dr. Reddy'S Labs | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
19.75 | 18.94 | 22.04 | 11.74 | 30.47 |
|
Asset Turnover
|
0.78 | 0.64 | 0.89 | 0.53 | 0.62 |
|
Receivable days
|
44.04 | 33.55 | 51.23 | 39.93 | 103.79 |
|
Inventory Days
|
50.59 | 33.80 | 48.93 | 51.78 | 79.94 |
|
Payable days
|
167.84 | 149.82 | 205.75 | 111.46 | 84.78 |
|
Cash Conversion Cycle
|
-73.22 | -82.46 | -105.59 | -19.75 | 98.95 |